Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.61 |
| ▸ | MAOB | P27338 | 1/20 | 0.61 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.61 |
| ▸ | DPP4 | P27487 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 14/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 14/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3155718 | 0.83 | OPRM1 (0.51) | MAOAMAOBTAAR1DPP4SLC6A3 | |
| SCHEMBL3261907 | 0.78 | SLC6A3 (0.41) | MAOAMAOBTAAR1DPP4SLC6A3 | |
| SCHEMBL5642275 | 0.77 | MAOA (0.35) | MAOAMAOBTAAR1SLC6A3SLC6A4 | |
| SCHEMBL5645623 | 0.77 | SLC6A2 (0.37) | MAOAMAOBTAAR1SLC6A4SLC6A2 | |
| SCHEMBL8352672 | 0.77 | MAOA (0.61) | MAOAMAOBTAAR1DPP4SLC6A3 | |
| SCHEMBL7898281 | 0.77 | MAOA (0.61) | MAOAMAOBTAAR1DPP4SLC6A3 | |
| SCHEMBL987779 | 0.77 | MAOA (0.61) | MAOAMAOBTAAR1DPP4SLC6A3 | |
| SCHEMBL1672926 | 0.77 | SLC6A3 (0.81) | MAOAMAOBTAAR1DPP4SLC6A3 | |
| SCHEMBL1672596 | 0.77 | SLC6A3 (0.81) | MAOAMAOBTAAR1DPP4SLC6A3 | |
| SCHEMBL3160203 | 0.77 | OPRM1 (0.42) | MAOAMAOBTAAR1DPP4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021130638-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | CARNA BIOSCIENCES, INC. (JP) | 2021-07-01 | — | — | WO | disclosed |
| WO-2011058149-A1 | TRICYCLIC PYRAZOL AMINE DERIVATIVES | MERCK SERONO S.A. (CH) | 2011-05-19 | — | — | WO | disclosed |
| US-7312214-B2 | 1, 1-disubstituted cycloalkyl derivatives as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-25 | — | — | US | disclosed |
| US-20040254158-A1 | Anticoagulants; atherosclerosis; strokes; thrombosis; cardiovascular disorders | BRISTOL-MYERS SQUIBB COMPANY | 2004-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254158-A1 | Anticoagulants; atherosclerosis; strokes; thrombosis; cardiovascular disorders | SERPINC1, PCSK9, PLAT | MAOA 1032/4885MAOB 694/4885TAAR1 1969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.